WE ARE UNLOCKING NEW
THERAPIES FOR GENETIC FORMS
OF OBESITY AND BLINDNESS

Discover Our Science

Axovia’s Solution

How Axovia was Founded

After decades of helping people with ciliopathies to manage their medical conditions without dedicated treatments, Professor Phil Beales and Dr. Victor Hernandez co-founded Axovia to develop treatments to address the disease burden for this group of disorders.

Lead Program

While there are more than 25 genes linked to Bardet-Biedl Syndrome (BBS), we are developing our lead program for the 40% of people with the disorder who carry two mutations in the BBS1 gene. Our novel gene therapy utilizes an adeno-associated virus (AAV9) to deliver a functional copy of the faulty BBS gene in key tissues as we seek to prevent blindness and reverse obesity.